Nykode Therapeutics Announces First Subject Dosed With Its T Cell Focused Next-generation SARS-CoV-2 Vaccine Candidate
Published by The Street By GlobeNewswire First subject dosed with Nykode Therapeutics’ T cell focused SARS-CoV-2 vaccine candidate. This is part of the ongoing phase 1/2 two-arm clinical trial VB-D-01